


AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all previous claims, and listings of claims, in the application.

1. (Previously Presented) An octahydronaphthalene compound represented by the following formula (1):



[ 1 ]

wherein R represents carboxy, hydroxymethyl, alkoxymethyl, alkoxycarbonyl, or  $-\text{CONR}^1\text{R}^2$ ;

$\text{R}^1$  and  $\text{R}^2$  are the same or different and each represents an alkyl group and wherein said alkyl group is substituted by

- 1) 2-pyridyl;
- 2) 3-pyridyl; or
- 3) 4-pyridyl,

or a pharmaceutically acceptable salt thereof wherein R represents  $-\text{CONR}^1\text{R}^2$  and one of either  $\text{R}^1$  or  $\text{R}^2$  represents a hydrogen atom, phenyl or alkyl; and the other variable represents alkyl substituted by 2-pyridyl, 3-pyridyl, or 4-pyridyl.

2. (Previously Presented) The octahydronaphthalene compound according to claim 1, which is N-(pyridin-3-ylmethyl)-(2E,4E)-5-[(1S,2S,4aR,6R,7S,8S,8aS)-7-hydroxy-2,6,8-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-2-methylpenta-2,4-dienamide, or a pharmaceutically acceptable salt thereof.

3. (Previously Presented) A pharmaceutical composition, which comprises the octahydronaphthalene compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

4 -15. (Cancelled)

16. (Previously Presented) A method for treating a cancer chosen from the group consisting of lung, prostate, pancreas and fibrosarcoma, which comprises administering to a subject in need thereof an effective amount of the octahydronaphthalene compound according to claim 1 or a pharmaceutically acceptable salt thereof.

17 -18. (Cancelled)